Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

2,679 public trials 158 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

NCT00740051

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.50.10009 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1218.50.10011 Boehringer Ingelheim Investigational Site Peoria, Arizona, United States
  • 1218.50.10013 Boehringer Ingelheim Investigational Site Greenbrae, California, United States
  • 1218.50.10016 Boehringer Ingelheim Investigational Site Harbor City, California, United States
View all 53 locations
View Trial Details
Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

NCT00935220

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.55.0006 Boehringer Ingelheim Investigational Site Cypress, California, United States
  • 1218.55.0008 Boehringer Ingelheim Investigational Site DeLand, Florida, United States
  • 1218.55.0004 Boehringer Ingelheim Investigational Site Miami, Florida, United States
  • 1218.55.0005 Boehringer Ingelheim Investigational Site Baltimore, Maryland, United States
View Trial Details
Completed

12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

NCT00789035

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.9.54001 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
  • 1245.9.54002 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
  • 1245.9.54007 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
  • 1245.9.54008 Boehringer Ingelheim Investigational Site Capital Federal, Argentina
View all 74 locations
View Trial Details
Completed

Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus

NCT01193218

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1245.38.016 Boehringer Ingelheim Investigational Site Chiyoda-ku, Tokyo, Japan
  • 1245.38.001 Boehringer Ingelheim Investigational Site Chuo-ku, Tokyo, Japan
  • 1245.38.003 Boehringer Ingelheim Investigational Site Chuo-ku, Tokyo, Japan
  • 1245.38.002 Boehringer Ingelheim Investigational Site Hachioji, Tokyo, Japan
View all 32 locations
View Trial Details

Related conditions